Progress of individualized treatment in Waldenström macroglobulinemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 193-197, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-806461
ABSTRACT
Waldenström macroglobulinemia (WM) is a rare lymphoma without a curable treatment method, which is characterized by MYD88 and CXCR4 gene mutations. The study on clinical manifestations, the pathological and genomic features has led to a series of promising clinical protocols. This article reviews the safety and efficacy of drugs including alkylating agents, proteasome inhibitors, monoclonal antibodies, and Bruton tyrosine kinase (BTK) inhibitors in WM patients combined with the latest research of the individualized treatment for WM at the 59th American Society of Hematology (ASH) Annual Meeting, so as to analyze the feasibility of basic genomic treatment and current integrated regimens for WM.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS